Literature DB >> 10931001

Deletion of the 5'-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients.

C Herens1, F Tassin, V Lemaire, Y Beguin, E Collard, S Lampertz, C Croisiau, M Lecomte, B De Prijk, L Longrée, L Koulischer.   

Abstract

Inclusion of the BCR-ABL ES probe in routine cytogenetics led to the identification of a subgroup of Philadelphia positive (Ph+) chronic myeloid leukaemia patients characterized by a 5'-ABL deletion. This anomaly was observed in 5/51 cases (9.8%). Cytological and clinical data suggest that the 5'-ABL deletion may be associated with dysplastic features of polymorphonuclear cells and metamyelocytes and a short chronic phase duration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931001     DOI: 10.1046/j.1365-2141.2000.02142.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

Review 1.  Predicting the response of CML patients to tyrosine kinase inhibitor therapy.

Authors:  Deborah L White; Timothy P Hughes
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

2.  Application of tri-colour, dual fusion fluorescence in situ hybridization (FISH) system for the characterization of BCR-ABL1 fusion in chronic myelogenous leukaemia (CML) and residual disease monitoring.

Authors:  Lisa Lp Siu; Edmond Sk Ma; Wai Shan Wong; Man Hong Chan; Kit Fai Wong
Journal:  BMC Blood Disord       Date:  2009-07-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.